Adverum Biotechnologies announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency as granted Ixo-vec, an investigational gene therapy for the treatment of wet AMD, an Innovation Passport under the Innovative Licensing and Access Pathway. The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the National Institute for Health and Care Excellence and the National Health Service England, to partner with Adverum to charter a roadmap for regulatory and development milestones with the goal of early patient access in the United Kingdom.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADVM:
- Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD
- Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting
- Adverum Biotechnologies reports Q4 EPS (33c), consensus (36c)
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
- Adverum Biotechnologies initiated with a Buy at Ladenburg
Questions or Comments about the article? Write to editor@tipranks.com